MOlecular profiling – pro
Beginning in April 2020, NCCN added a broad, non-cancer specific recommendation, Version 4.2020, “The NCCN Panel recommends that metastatic disease at presentation or first recurrence of disease should be biopsied as a part of the workup for patients with recurrent or stage IV disease. This ensures accurate determination of metastatic/recurrent disease and tumor histology, and allows for biomarker determination and selection of appropriate treatment. Soft tissue tumor biopsy is preferred over bone sites unless a portion of the biopsy can be protected from harsh decalcification solution to preserve more accurate assessment of biomarkers. ….Genetic testing: In the metastatic setting, results from genetic testing may have therapeutic implications.”
Wafik S. ElDeiry et al, The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA-Cancer Journ Clin Volume69, Issue4 July/August 2019 Pages 305-343
Clark et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. The Journal of Molecular Diagnostics. 2018.
Clark TA, Chung JH, Kennedy M, et al. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagn 2018;20(5):686‐702. doi:10.1016/j.jmoldx.2018.05.004
Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer. 2013;5:61-70. Published 2013 Oct 29.
Carter P, Alifrangis C, Xerese B, et al. Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. Oncotarget. 2018; 9(25): 17589-17596. Published 2018 Feb 24.